3,737 research outputs found
S. Prosper Aquitanus
No full textPROSPER AQUITANUS (s.). Epigrammata e sententiis s. AugustiniPROSPER AQUITANUS (s.). Poema conjugis ad uxorem cum glossisNumérisation effectuée à partir d'un document de substitution.F. 1v-33v [Epigrammata] (P. L., LI, 497-532) précédé d'un accessus sur Prosper d'Aquitaine : « Iste Prosper fuit equitanicus, vir eruditissimus... » (1 et 2), et de dix vers : « Hec Agustini ex sacris epigramata dictis... » (1-1v et 2). Texte sans rubriques ni compte des chapitres. Gloses marginales et interlinéaires qui reproduisent en partie celles du ms. 2774A. Le texte commence au f. 2, le f. 1 et v° n'est que la copie de la préface, des dix vers : « Hec Agustini... » et des 15 premiers vers de l'ouvrage. F. 33v-36 [Poema conjugis ad uxorem] douteux : « Age jam precor mearum... » (C. S. E. L., XXX, 344-348) le texte suit celui des Epigrammes sans rubriques et sans transition. Gloses marginales et interlinéaires : « Hortatur uxorem suam... ». — Au f. 36v : « Finito libro isto sit laus et gloria Christo || qui scripsit scribat semper cum Domino vivat. || Vivat in celis Leonardus nomine Felix. || Explicit bactiste qui Prosper dicitur iste.
Catalogue des livres qui se trouvent chez Siméon-Prosper Hardy, libraire à Paris, rue S. Jacques au dessus de celle de la Parcheminerie, à la Colonne d'or, 1759
No full text[Catalogue de libraire. Paris. Hardy, Siméon-Prosper. 1759]Avec mode text
Catalogue des livres qui se trouvent chez Siméon-Prosper Hardy, libraire à Paris, rue S. Jacques au-dessus de celle de la Parcheminerie, à la Colonne d'or, 1760
No full text[Catalogue de libraire. Paris. Hardy, Siméon-Prosper. 1760]Avec mode text
Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
No full text<p>Background: Venous thromboembolic events (VTE), including deep venous thrombosis and pulmonary embolism, are common in older age. It has been suggested that statins might reduce the risk of VTE however positive results from studies of middle aged subjects may not be generalisable to elderly people. We aimed to determine the effect of pravastatin on incident VTE in older people; we also studied the impact of clinical and plasma risk variables.</p>
<p>Methods: This study was an analysis of incident VTE using data from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), a randomized, double-blind, placebo-controlled trial of pravastatin in men and women aged 70-82. Mean follow-up was 3.2 years. Risk for VTE was examined in non-warfarin treated pravastatin (n = 2834) and placebo (n = 2865) patients using a Cox's proportional hazard model, and the impact of other risk factors assessed in a multivariate forward stepwise regression analysis. Baseline clinical characteristics, blood biochemistry and hematology variables, plasma levels of lipids and lipoproteins, and plasma markers of inflammation and adiposity were compared. Plasma markers of thrombosis and hemostasis were assessed in a nested case (n = 48) control (n = 93) study where the cohort was those participants, not on warfarin, for whom data were available.</p>
<p>Results: There were 28 definite cases (1.0%) of incident VTE in the pravastatin group recipients and 20 cases (0.70%) in placebo recipients. Pravastatin did not reduce VTE in PROSPER compared to placebo [unadjusted hazard ratio (95% confidence interval) 1.42 (0.80, 2.52) p = 0.23]. Higher body mass index (BMI) [1.09 (1.02, 1.15) p = 0.0075], country [Scotland vs Netherlands 4.26 (1.00, 18.21) p = 0.050 and Ireland vs Netherlands 6.16 (1.46, 26.00) p = 0.013], lower systolic blood pressure [1.35 (1.03, 1.75) p = 0.027] and lower baseline Mini Mental State Examination (MMSE) score [1.19 (1.01, 1.41) p = 0.034] were associated with an increased risk of VTE, however only BMI, country and systolic blood pressure remained significant on multivariate analysis. In a nested case control study of definite VTE, plasma Factor VIII levels were associated with VTE [1.52 (1.01, 2.28), p = 0.044]. However no other measure of thrombosis and haemostasis was associated with increased risk of VTE.</p>
<p>Conclusions: Pravastatin does not prevent VTE in elderly people at risk of vascular disease. Blood markers of haemostasis and inflammation are not strongly predictive of VTE in older age however BMI, country and lower systolic blood pressure are independently associated with VTE risk.</p>
Replication of LDL SWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses
No full text<p><b>Background:</b> The PHArmacogenetic study of Statins in the Elderly at risk (PHASE) is a genome wide association study in the PROspective Study of Pravastatin in the Elderly at risk for vascular disease (PROSPER) that investigates the genetic variation responsible for the individual variation in drug response to pravastatin. Statins lower LDL-cholesterol in general by 30%, however not in all subjects. Moreover, clinical response is highly variable and adverse effects occur in a minority of patients. In this report we first describe the rationale of the PROSPER/PHASE project and second show that the PROSPER/PHASE study can be used to study pharmacogenetics in the elderly.</p>
<p><b>Methods:</b> The genome wide association study (GWAS) was conducted using the Illumina 660K-Quad beadchips following manufacturer's instructions. After a stringent quality control 557,192 SNPs in 5,244 subjects were available for analysis. To maximize the availability of genetic data and coverage of the genome, imputation up to 2.5 million autosomal CEPH HapMap SNPs was performed with MACH imputation software. The GWAS for LDL-cholesterol is assessed with an additive linear regression model in PROBABEL software, adjusted for age, sex, and country of origin to account for population stratification.</p>
<p><b>Results:</b> Forty-two SNPs reached the GWAS significant threshold of p = 5.0e-08 in 5 genomic loci (APOE/APOC1; LDLR; FADS2/FEN1; HMGCR; PSRC1/CELSR5). The top SNP (rs445925, chromosome 19) with a p-value of p = 2.8e-30 is located within the APOC1 gene and near the APOE gene. The second top SNP (rs6511720, chromosome 19) with a p-value of p = 5.22e-15 is located within the LDLR gene. All 5 genomic loci were previously associated with LDL-cholesterol levels, no novel loci were identified. Replication in WOSCOPS and CARE confirmed our results.</p>
<p><b>Conclusion:</b> With the GWAS in the PROSPER/PHASE study we confirm the previously found genetic associations with LDL-cholesterol levels. With this proof-of-principle study we show that the PROSPER/PHASE study can be used to investigate genetic associations in a similar way to population based studies. The next step of the PROSPER/PHASE study is to identify the genetic variation responsible for the variation in LDL-cholesterol lowering in response to statin treatment in collaboration with other large trials.</p>
Bois pour gravures, cadres et encadrements pour artistes. G. Zay...
No full textRéférence bibliographique : IFF19 Isaac (Prosper-Alphonse), 16Appartient à l’ensemble documentaire : FranceJp0Image publicitair
Prosper pilot case study : Woodburn
No full textProsper is a national tourism research project commissioned by the Sustainable Tourism Cooperative Research
Centre (STCRC) and managed by the Centre for Regional Tourism Research, Southern Cross University.
Prosper involves researchers from Southern Cross University, the University of Queensland and Murdoch
University. Prosper aims to develop context specific and holistic models for evaluating the capacity of regional
communities to use innovation as a means of harnessing tourism’s social, economic and environmental value.
This document presents the findings from the preliminary Prosper case study conducted in the northern New
South Wales community of Woodburn.
The core of the Prosper program is a series of case studies of regional tourism innovation potential. Prosper
is not designed to tell case study communities what tourism development they should undertake. Rather, the
research allows increased understanding of the way tourism operates in these communities, and identifies
potential challenges the community will face in trying to develop tourism. At the same time, it identifies some
strengths that can be brought to the tourism planning and management processes in those communities.
The key questions for the Prosper project are:
1. What structures in regional tourism management work best in different systems to create environments
of innovation?
2. Where in the system (or external to it) do regional tourism innovations come from, and how can
regional tourism managers recognise an innovative idea or action?
3. What techniques can be used to evaluate the impacts of innovation on dimensions of regional
development?
4. What aspects of social, cultural, economic and political capital are important to innovation and strategic
development?
Like all research, Prosper will be of use to communities if there are local champions committed to taking the
information and acting on it. Those champions will need to understand the way in which the research has been
produced, and will view the research as one component of the knowledge required to inform destination
management.
This report contains the findings from the Prosper pilot study. It introduces the reader to the case study,
Woodburn, with a range of descriptive information about the general township, as well as issues such as social
and economic capacities and the tourism system. This overview then enables the report to present an analysis of
Woodburn using a collection of innovation capacity contexts presented in the ‘methodologies’ report cited
above. Emerging from the Woodburn case study analysis is a checklist of Woodburn capacity for innovation
indicators relating to each innovation context observed during the analysis. The checklist will highlight the
utility of the Prosper research approach by providing a resource to help better understand the regional framework
and interrelationships needed for regional communities, in this case Woodburn, to engage in innovative regional
tourism development. A glossary has been added to the rear of this report to help clarify any terms that seem
unclear or ambiguous
C-Reactive protein and genetic variants and cognitive decline in old age: the PROSPER Study
No full textBackground: Plasma concentrations of C-reactive protein (CRP), a marker of chronic inflammation, have been associated with cognitive impairment in old age. However, it is unknown whether CRP is causally linked to cognitive decline.
Methods and Findings: Within the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trial, with 5680 participants with a mean age of 75 years, we examined associations of CRP levels and its genetic determinants with cognitive performance and decline over 3.2 years mean follow-up. Higher plasma CRP concentrations were associated with poorer baseline performance on the Stroop test (P = 0.001) and Letter Digit Tests (P, 0.001), but not with the immediate and delayed Picture Learning Test (PLT; both P>0.5). In the prospective analyses, higher CRP concentrations associated with increased rate of decline in the immediate PLT (P = 0.016), but not in other cognitive tests (all p>0.11). Adjustment for prevalent cardiovascular risk factors and disease did not change the baseline associations nor associations with cognitive decline during follow-up. Four haplotypes of CRP were used and, compared to the common haplotype, carrierships associated strongly with levels of CRP (all P < 0.007). In comparison to strong associations of apolipoprotein E with cognitive measures, associations of CRP haplotypes with such measures were inconsistent.
Conclusion: Plasma CRP concentrations associate with cognitive performance in part through pathways independent of (risk factors for) cardiovascular disease. However, lifelong exposure to higher CRP levels does not associate with poorer cognitive performance in old age. The current data weaken the argument for a causal role of CRP in cognitive performance, but further study is warranted to draw definitive conclusions
Development of an exercise intervention for the prevention of musculoskeletal shoulder problems after breast cancer treatment : the prevention of shoulder problems trial (UK PROSPER)
No full textBackground
Musculoskeletal shoulder problems are common after breast cancer treatment. There is some evidence to suggest that early postoperative exercise is safe and may improve shoulder function. We describe the development and delivery of a complex intervention for evaluation within a randomised controlled trial (RCT), designed to target prevention of musculoskeletal shoulder problems after breast cancer surgery (The Prevention of Shoulder Problems Trial; PROSPER).
Methods
A pragmatic, multicentre RCT to compare the clinical and cost-effectiveness of best practice usual care versus a physiotherapy-led exercise and behavioural support intervention in women at high risk of shoulder problems after breast cancer treatment. PROSPER will recruit 350 women from approximately 15 UK centres, with follow-up at 6 and 12 months. The primary outcome is shoulder function at 12 months; secondary outcomes include postoperative pain, health related quality of life, adverse events and healthcare resource use. A multi-phased approach was used to develop the PROSPER intervention which was underpinned by existing evidence and modified for implementation after input from clinical experts and women with breast cancer. The intervention was tested and refined further after qualitative interviews with patients newly diagnosed with breast cancer; a pilot RCT was then conducted at three UK clinical centres.
Discussion
The PROSPER intervention incorporates three main components: shoulder-specific exercises targeting range of movement and strength; general physical activity; and behavioural strategies to encourage adherence and support exercise behaviour. The final PROSPER intervention is fully manualised with clear, documented pathways for clinical assessment, exercise prescription, use of behavioural strategies, and with guidance for treatment of postoperative complications. This paper adheres to TIDieR and CERT recommendations for the transparent, comprehensive and explicit reporting of complex interventions.
Trial registration: International Standard Randomised Controlled Trial Number: ISRCTN 35358984
Prosper School District No. 23 records, 1884-1966.
No full textThe Prosper School District #23 Records cover 1892-1962. The miscellaneous records include school inventories, inspection records, and accreditation certificates. Other records include PTA minutes, Clerk?s Records, and Teacher?s Registers
- …
